News-CDMO
CDMO activity: Head of Development & Manufacturing for Polygon Therapeutics (Sept 2022)
Development & Manufacturing of POLYGON therapeutic leader product PLG-101, a monoclonal antibody for the treatment of cardiovascular diseases (myocardial infacrtion). The antibody PLG-101 aims to enhance post-ischemic cardiac remodeling. Christian Bailly (Oncowitan) brings his exertise to guide the manufacturing of the producing cell line and GMP-made antibody, for subsequent clinical Read more…
